focus -WSS

focus

author：comprehensive 2025-08-23 05:00:42 - browse：73

Adobe

The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan, which led to the health insurance company in California losing hundreds of millions of dollars in bonuses from the government, a judge ruled Monday.

The decision will lead to more than $250 million funneling back into SCAN, which covers 270,000 Medicare Advantage enrollees. And it opens the door for other Medicare Advantage plans to potentially recoup huge sums of taxpayer-funded bonuses — even though many independent experts believe the quality rating system is flawed and doesn’t appropriately gauge quality of care for older adults and people with disabilities.

The Centers for Medicare and Medicaid Services, the federal agency that oversees all Medicare programs, said it does not comment on litigation. In an interview, SCAN CEO Sachin Jain told STAT that if the company had not gotten its expected bonus money, it would have had to shave benefits and reduce what it pays hospitals and doctors.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

explore

WSS

In utero gene editing: an explainer

BIO selects John Crowley as new CEO

The EPA's new lead rule: How one expert crunched the numbers

The EPA's new lead rule: How one expert crunched the numbers

R1 RCM gets $5.8 billion buyout offer from private equity firm

CDC director unscathed in first congressional testimony

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

CDC director unscathed in first congressional testimony

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Alkermes shareholders re

Organ aging and disease risk measured by new blood test

Medicare details structure of new drug price negotiation program

Mayo Clinic plans $5B tech

BioMarin wins approval for gene therapy to treat hemophilia A

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

explore

NIH study of ME/CFS points to clear biological hallmarks

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

6 phony surgeries that take placebo to the extreme

R1 RCM gets $5.8 billion buyout offer from private equity firm

UnitedHealth’s Optum accused of antitrust violations in California

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Wikipedia

explore

hotspot

focus